SK Chemicals Co., Ltd.
https://www.skchemicals.com/main.do
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From SK Chemicals Co., Ltd.
Lebrikizumab Among Nine Drugs To Get EMA Nod; PTC Faces Disappointment For Translarna
The European Medicines Agency has OKd nine new medicines for EU-wide approval, but recommended against renewing the conditional marketing authorization of two drugs.
Asia Deal Watch: Kelun Partners With Merck A Third Time, Optioning Rights To Seven ADCs
Already partnered on antibody-drug conjugates and a Phase III breast cancer candidate, Merck could pay up to $9.3bn under its third pact in 2022 with Kelun. Eisai divests Fycompa to Catalyst.
TiumBio CEO On Successful Partnerships, Ambitions To Develop The Next Afstyla
TiumBio’s CEO shares his experiences as the original developer of hemophilia therapy Afstyla, the reason the rare disease-specialized company is exploring opportunities in Australia, as well as its R&D plans.
Hopes Rise For SK’s COVID-19 Vaccine As It Moves To Comparative Phase III Trial
Following positive interim Phase I/II results, expectations are rising for SK Bioscience’s recombinant COVID-19 vaccine as it becomes the first Korea-developed candidate to progress to Phase III.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Dongshin Pharma
- SK Bioscience
- SK chemicals qingdao SK chemicals suzhou
- INITZ
- ENTIS
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice